ID-5184 Wonca Abstracts supplement A-K 13-10-23 - Flipbook - Page 192
WONCA 2023 Supplement 1: WONCA 2023 abstracts (A–K)
A
B
C
D
The 2023 update of the international evidence-based
guidelines on polycystic ovary syndrome: What GPs need
to know
A/Prof Carolyn Ee1, Prof Lisa Moran2, Michael Costello3,4, Lisa Bedson5
1
E
F
G
H
I
J
K
NICM Health Research Institute, Western Sydney University, 2Monash Centre for Health Research and
Implementation, Monash University, 3Women’s Health, School of Clinical Medicine, UNSW and Royal
Hospital for Women, 4Monash IVF, Sydney, 5Repromed, South Australia
Polycystic ovary syndrome (PCOS) is a significant public health issue with reproductive,
cardiometabolic, dermatological and psychological features, affecting around 10% of reproductiveaged women. Given the complex and chronic nature of the syndrome, GPs are ideally placed to
provide comprehensive and whole-person healthcare to adolescents and women with PCOS.
The international evidence-based guideline for the assessment and management of PCOS is designed
to provide clear information to assist clinical decision making and support optimal patient care.
The guideline was updated in 2023 and integrates the best available evidence with multidisciplinary
expertise (including primary care representatives) and consumer preferences. It followed rigorous
Appraisal of Guidelines for Research and Evaluation (AGREE-II)-compliant evidence-based guideline
processes, and provides a single source of international evidence-based recommendations to guide
clinical practice worldwide.
This professional forum provides GPs and family physicians with an update on the assessment and
management of PCOS according to the newly updated guidelines. The clinical questions that were
prioritised in the guideline were informed by an international Delphi study and a stakeholder survey
(with a focus on consumers with PCOS). The guideline covers five major clinical areas: (1) screening,
diagnostic assessment, risk assessment and life stage; (2) prevalence, screening, diagnostic
assessment and treatment of emotional wellbeing; (3) lifestyle; (4) management of non-fertility features;
and (5) assessment and treatment of infertility.
This professional forum is presented by a multidisciplinary team (GPs, dietician, obstetrician/
gynaecologist and reproductive endocrinologist) who contributed significantly to the guideline as
chairs/members of guideline development groups.
We will use a case-based approach to take GPs through the guideline recommendations. There will
be a brief presentation from each presenter followed by a panel discussion on practical aspects, and
barriers/enablers of the application of the guideline recommendations into primary care globally, as
well as a Q&A session.
190